Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities

Cancer Immunology, Immunotherapy

Volumn 66, Issue 8, 2017, Pages 979-988

  Kortylewski, Marcin ^a   Moreira, Dayson ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

CpG; MDSC; Oligonucleotides; Regulatory myeloid suppressor cells; STAT3; TLR9

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; NUCLEASE; OLIGONUCLEOTIDE; PROTEIN INHIBITOR; SMALL INTERFERING RNA; STAT3 PROTEIN; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST;

ACUTE MYELOID LEUKEMIA; B CELL LYMPHOMA; BONE MARROW CELL; CANCER CELL; CELL SELECTION; CELL SURVIVAL; CONJUGATION; IN VIVO STUDY; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SOLID MALIGNANT NEOPLASM; T LYMPHOCYTE; TUMOR IMMUNOGENICITY; ANIMAL; ANTAGONISTS AND INHIBITORS; CPG ISLAND; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; CPG ISLANDS; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; MYELOID-DERIVED SUPPRESSOR CELLS; OLIGONUCLEOTIDES; STAT3 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR 9;

EID: 85013124291     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-017-1966-2     Document Type: Review

References (55)

1. Topalian SL, Weiner GJ, Pardoll DM (2011) Cancer immunotherapy comes of age. J Clin Oncol 29:4828–4836. doi:10.1200/JCO.2011.38.0899
2. Turley SJ, Cremasco V, Astarita JL (2015) Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol 15:669–682. doi:10.1038/nri3902
3. Gajewski TF (2015) The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment. Semin Oncol 42:663–671. doi:10.1053/j.seminoncol.2015.05.011
4. Kammertoens T, Schüler T, Blankenstein T (2005) Immunotherapy: target the stroma to hit the tumor. Trends Mol Med 11:225–231. doi:10.1016/j.molmed.2005.03.002
5. Fang H, Declerck YA (2013) Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res 73:4965–4977. doi:10.1158/0008-5472.CAN-13-0661
6. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12:253–268. doi:10.1038/nri3175
7. Engblom C, Pfirschke C, Pittet MJ (2016) The role of myeloid cells in cancer therapies. Nat Rev Cancer 16:447–462. doi:10.1038/nrc.2016.54
8. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41–51. doi:10.1038/nri1995
9. Wang T, Niu G, Kortylewski M et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48–54. doi:10.1038/nm976
10. Kortylewski M, Kujawski M, Wang T et al (2005) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11:1314–1321. doi:10.1038/nm1325
11. Kujawski M, Kortylewski M, Lee H et al (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118:3367–3377. doi:10.1172/JCI35213
12. Gao C, Kozlowska A, Nechaev S et al (2013) TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy. Cancer Res 73:7211–7221. doi:10.1158/0008-5472.CAN-13-1314
13. Hillmer EJ, Zhang H, Li HS, Watowich SS (2016) STAT3 signaling in immunity. Cytokine Growth Factor Rev. doi:10.1016/j.cytogfr.2016.05.001
14. Kortylewski M, Xin H, Kujawski M et al (2009) Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15:114–123. doi:10.1016/j.ccr.2008.12.018
15. Haddad E (2015) STAT3: too much may be worse than not enough! Blood 125:583–584. doi:10.1182/blood-2014-11-610592
16. + T cells. Immunity 35:792–805. doi:10.1016/j.immuni.2011.09.017
17. Siegel AM, Heimall J, Freeman AF et al (2011) A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity 35:806–818. doi:10.1016/j.immuni.2011.09.016
18. Kortylewski M, Kujawski M, Herrmann A et al (2009) Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res 69:2497–2505. doi:10.1158/0008-5472.CAN-08-3031
19. Sen M, Grandis JR (2012) Nucleic acid-based approaches to STAT inhibition. JAKSTAT 1:285–291. doi:10.4161/jkst.22312
20. Kontzias A, Kotlyar A, Laurence A et al (2012) Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 12:464–470. doi:10.1016/j.coph.2012.06.008
21. Ratner M (2014) Setback for JAK2 inhibitors. Nat Biotechnol 32:119–119. doi:10.1038/nbt0214-119a
22. Kortylewski M, Nechaev S (2014) Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver? Ther Deliv 5:239–242. doi:10.4155/tde.13.152
23. Krieg AM (2012) CpG still rocks! Update on an accidental drug. Nucl Acid Ther 22:77–89. doi:10.1089/nat.2012.0340
24. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987–995. doi:10.1038/ni1112
25. Canton J, Neculai D, Grinstein S (2013) Scavenger receptors in homeostasis and immunity. Nat Rev Immunol 13:621–634. doi:10.1038/nri3515
26. Gursel M, Gursel I, Mostowski HS, Klinman DM (2006) CXCL16 influences the nature and specificity of CpG-induced immune activation. J Immunol 177:1575–1580
27. Zhu P, Liu X, Treml LS et al (2009) Mechanism and regulatory function of CpG signaling via scavenger receptor B1 in primary B cells. J Biol Chem 284:22878–22887. doi:10.1074/jbc.M109.018580
28. Nechaev S, Gao C, Moreira D et al (2013) Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape. J Control Release 170:307–315. doi:10.1016/j.jconrel.2013.06.007
29. Józefowski S, Sulahian TH, Arredouani M, Kobzik L (2006) Role of scavenger receptor MARCO in macrophage responses to CpG oligodeoxynucleotides. J Leukoc Biol 80:870–879. doi:10.1189/jlb.0705357
30. Baumann CL, Aspalter IM, Sharif O et al (2010) CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med 207:2689–2701. doi:10.1084/jem.20101111
31. Lahoud MH, Ahmet F, Zhang J-G et al (2012) DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc Natl Acad Sci USA 109:16270–16275. doi:10.1073/pnas.1208796109
32. Sirois CM, Jin T, Miller AL et al (2013) RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med 210:2447–2463. doi:10.1084/jem.20120201
33. McKelvey KJ, Highton J, Hessian PA (2011) Cell-specific expression of TLR9 isoforms in inflammation. J Autoimmun 36:76–86. doi:10.1016/j.jaut.2010.11.001
34. Shatz M, Menendez D, Resnick MA (2012) The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res 72:3948–3957. doi:10.1158/0008-5472.CAN-11-4134
35. Hossain DMS, Pal SK, Moreira D et al (2015) TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients. Clin Cancer Res 21:3771–3782. doi:10.1158/1078-0432.CCR-14-3145
36. Zhang Q, Hossain DMS, Nechaev S et al (2013) TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood 121:1304–1315. doi:10.1182/blood-2012-07-442590
37. Moreira D, Zhang Q, Hossain DMS et al (2015) TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells. Oncotarget 6:17302–17313. doi:10.18632/oncotarget.4029
38. Herrmann A, Cherryholmes G, Schroeder A et al (2014) TLR9 is critical for glioma stem cell maintenance and targeting. Cancer Res 74:5218–5228. doi:10.1158/0008-5472.CAN-14-1151
39. Rajora MA, Zheng G (2016) Targeting SR-BI for cancer diagnostics, imaging and therapy. Front Pharmacol 7:326. doi:10.3389/fphar.2016.00326
40. Kortylewski M, Swiderski P, Herrmann A et al (2009) In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 27:925–932. doi:10.1038/nbt.1564
41. Hossain DMS, Moreira D, Zhang Q et al (2016) TLR9-targeted SiRNA delivery in vivo. Methods Mol Biol 1364:183–196. doi:10.1007/978-1-4939-3112-5_15
42. Zhang Q, Hossain DMS, Duttagupta P et al (2016) Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood 127:1687–1700. doi:10.1182/blood-2015-08-665604
43. Hossain DMS, Santos C Dos, Zhang Q et al (2014) Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood 123:15–25. doi:10.1182/blood-2013-07-517987
44. Ma Y, Kowolik CM, Swiderski PM et al (2011) Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA. ACS Chem Biol 6:962–970. doi:10.1021/cb200176v
45. Nakamura N, Lill JR, Phung Q et al (2014) Endosomes are specialized platforms for bacterial sensing and NOD2 signalling. Nature 509:240–244. doi:10.1038/nature13133
46. Herrmann A, Kortylewski M, Kujawski M et al (2010) Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res 70:7455–7464. doi:10.1158/0008-5472.CAN-10-0736
47. Marvel D, Gabrilovich DI (2015) Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 125:3356–3364. doi:10.1172/JCI80005
48. Bronte V, Brandau S, Chen S-H et al (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7:12150. doi:10.1038/ncomms12150
49. Vasquez-Dunddel D, Pan F, Zeng Q et al (2013) STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 123:1580–1589. doi:10.1172/JCI60083
50. De Veirman K, Van Valckenborgh E, Lahmar Q et al (2014) Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front Oncol 4:349. doi:10.3389/fonc.2014.00349
51. Kumar V, Patel S, Tcyganov E, Gabrilovich DI (2016) The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 37:208–220. doi:10.1016/j.it.2016.01.004
52. Cheng F, Wang H, Horna P et al (2012) Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity. Cancer Res 72:4440–4448. doi:10.1158/0008-5472.CAN-11-3619
53. Decker T, Schneller F, Sparwasser T et al (2000) Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 95:999–1006
54. Darnell JE (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2:740–749. doi:10.1038/nrc906
55. Zhang B, Li L, Chen C et al (2015) Knockdown (KD) of Mir-126 expression enhances tyrosine kinase inhibitor (TKI)-mediated targeting of chronic myelogenous leukemia (CML) stem cells. 57th Annual Meeting of American Society of Hematology, oral presentation, Orlando, FL. Blood 126:51